RE:RE:RE:Sanofi Exploring Acquisition of KRAS Cancer Drugmaker MiratiMirati Therapeutics targets G12C KRAS cancers while ONC's pelareorep targets G12D the predominant target in pancreatic cancer and G12V in colorectal cancer, and Mirati’s market cap is US $4.2 Billion . Unfortunately the Cannacord Bank Robbers want the difference plus more.